Score Overview
Explore the 2021 public Archive ranking →
Where Tekla Life Sciences Investors has ranked, year by year
Showing 1 year ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- HQL
1998: 94.8% · 2021: 3.1% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 18.49 | — |
1 Year2025-09-29 | $ 13.48 | 37.13% |
5 Years2021-09-29 | $ 11.88 | 55.63% |
10 Years2016-09-29 | $ 6.93 | 166.68% |
20 Years2006-09-29 | $ 2.17 | 8x |
30 Years1996-09-27 | $ 0.82 | 22x |
All Time1992-05-04 | $ 0.82 | 22x |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | 30 Years1996-09-27 | All Time1992-05-04 |
|---|---|---|---|---|---|---|---|
| Price | $ 18.49 | $ 13.48 | $ 11.88 | $ 6.93 | $ 2.17 | $ 0.82 | $ 0.82 |
| Return | — | 37.13% | 55.63% | 166.68% | 8x | 22x | 22x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| 2025 | $ 86M | $ 85M | $ 75.54K |
| 2024 | $ 86M | $ 85M | $ 1.00 |
| 2023 | $ 23M | $ 22M | $ 15M |
| 2022 | -$ 103M | -$ 104M | $ 445.00 |
| 2021 | $ 65M | $ 64M | $ 990.00 |
| 2020 | $ 124M | $ 123M | $ 4M |
| 2019 | -$ 69M | -$ 70M | $ 1M |
| 2018 | $ 1M | $ 28M | $ 40.00 |
| 2017 | $ 69M | $ 68M | $ 615.31K |
| 2016 | $ 6M | -$ 11M | $ 9M |
| 2015 | $ 1M | $ 40M | $ 403.00 |
| 2014 | $ 876.79K | $ 89M | $ 2.34K |
| 2013 | $ 516.76K | $ 84M | $ 36.58K |
| 2012 | $ 2M | $ 77M | $ 689.00 |
| 2011 | $ 570K | $ 37M | |
| 2010 | $ 1M | $ 10M | |
| 2009 | $ 460K | -$ 21M | $ 5M |
| 2008 | $ 1M | $ 60M | |
| 2007 | $ 2M | $ 50M | |
| 2006 | $ 2M | -$ 21M | |
| 2005 | $ 890K | $ 44M | |
| 2004 | $ 320K | $ 7M | $ 700K |
| 2003 | $ 610K | $ 38M | $ 1M |
| 2002 | $ 940K | -$ 50M | $ 100K |
| 2001 | $ 1M | -$ 95M | $ 400K |
| 1998 | $ 140K | -$ 30M | |
| 1997 | $ 320K | $ 15M | $ 100K |
| 1996 | $ 420K | $ 21M | $ 200K |
Tekla Life Sciences Investors fundamental performance
Between 2020 and 2025, revenue declined from $ 124M to $ 86M and net income declined from $ 123M to $ 85M. Revenue increased in 2 of those 5 years; net income in 3.
Across Tekla Life Sciences Investors's full reported history, from 1996 to 2025, revenue grew from $ 420K to $ 86M and net income grew from $ 21M to $ 85M. Revenue increased in 48% of the years measured; net income in 56%.
Tekla Life Sciences Investors currently holds a 20-year HDB Score of 4.3 out of 10. How the HDB Score is calculated.
Membership
Continue HQL’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
